4.6 Article

No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes

Journal

DIABETES & METABOLISM
Volume 34, Issue 6, Pages 568-573

Publisher

MASSON EDITEUR
DOI: 10.1016/j.diabet.2008.05.010

Keywords

Cystic fibrosis; Glycated haemoglobin; Diabetes

Funding

  1. Montreal University Hospital Foundation (Fondation du CHUM) [8200]
  2. Fonds de Recherche en Sante du Qucbec (FRSQ)

Ask authors/readers for more resources

Aim. - Cystic fibrosis-related diabetes (CFRD) prevalence has increased dramatically with the improved life expectancy of patients with cystic fibrosis (CF). Glycated haernoglobin (HbA(1c)) is an important tool for monitoring blood glucose control but, unlike in type 1 and type 2 diabetes, a correlation between HbA(1c), fructosamine and mean plasma glucose has not been clearly established in CF. This study aimed to examine the relationship between mean plasma glucose and HbA(1c) or fructosamine in stable patients with CFRD. Methods. - Fifteen type 1 diabetes and 13 CFRD patients (HbA(1c) < 9.0% no anaemia). matched for age and body mass index (BMI), provided 72 capillary blood glucose profiles taken 3 days/month for three months. At the end of this time, HbA(1c) and fructosamine were measured. Mean plasma glucose was estimated using the Diabetes Control and Complications Trial (DCCT) conversion formula, and linear regressions carried out to establish its relationship with HbA(1c) and fructosamine. Results. - In type 1 diabetes patients, mean plasma glucose correlated significantly with HbA(1c) (r=0.68; P=0.005). In CFRD patients, no correlation was found between mean plasma glucose and HbA(1c) (r=0.24: P=0.460). Also, no association was found between mean plasma glucose, representing the month before blood sampling, and fructosamine in either group. Conclusion. - Unlike in type 1 diabetes, HbA(1c) did not correlate with mean plasma glucose in CFRD subjects. Thus, having a normal HbA(1c) may not be sufficient to indicate a low risk of diabetes complications in CFRD. Further Studies are required to explain such a discrepancy. (C) 2008 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available